Highest-materiality recent filing
Definitive Healthcare receives Nasdaq bid-price deficiency notice; has until Dec 15, 2026 to comply
Nasdaq notified Definitive Healthcare on June 18, 2026 that its stock failed to meet $1.00 minimum bid price for 30 consecutive days.
Definitive Healthcare Q1 revenue $55.9M (-6% YoY); net loss $192.4M on $197M goodwill impairment
Revenue of $55.9M, at top end of guidance, down 6% from $59.2M in Q1 2025.
Q4 revenue $61.5M vs $62.3M prior year; adjusted EBITDA $18.0M (29% margin) vs $17.5M (28%).
Definitive Healthcare Q3 revenue $60M (-4% YoY); net loss $17.8M; raises FY revenue guidance low end
Revenue $60.0M (-4% vs $62.7M in Q3 2024); net loss $17.8M (vs $187.8M including $228.2M goodwill impairment).
Definitive Healthcare Q2 revenue $60.8M (-5% YoY); raises FY revenue guidance bottom by $3M
Q2 net loss $(9.3)M vs $(306.2)M (prior year included $363.6M goodwill impairment).
Revenue $59.2M, down 7% YoY; net loss $155.1M including $176.5M goodwill impairment.
Definitive Healthcare Q4 revenue $62.3M (-6% YoY); guides FY2025 $230-240M; names Casey Heller CFO
Q4 revenue $62.3M, -6% YoY; net loss $(84.7)M including $97.1M goodwill impairment.
Q3 revenue $62.7M, down 4% YoY; net loss $(187.8)M includes $228.2M goodwill impairment; adjusted EBITDA $20.6M (33% margin).
Definitive Healthcare Q2 revenue $63.7M (+5% YoY); net loss $(306.2)M on $363.6M goodwill impairment
Revenue $63.7M (+5% YoY); net loss $(306.2)M including $363.6M goodwill impairment (up 2,538% from $(11.6)M).
Definitive Healthcare Q2 prelim revenue $63.7M (+5% YoY), goodwill impairment $363.6M; CRO resigns
Revenue $63.7M (+5% YoY); adjusted EBITDA $20.9M (33% margin) vs $17.2M (28%) YoY.
Appoints Kevin Coop as CEO effective June 24; Founder Krantz remains Executive Chairman
Kevin Coop appointed CEO effective June 24, 2024; founder Jason Krantz steps down as interim CEO but stays as Executive Chairman.
Definitive Healthcare Q1 revenue $63.5M (+7% YoY); Adj. EBITDA margin 32%; $20M buyback
Revenue $63.5M, +7% YoY from $59.2M; net loss narrowed to $12.7M from $16.0M.
Q4 revenue $65.9M (+9% YoY); FY23 revenue $251.4M (+13% YoY).
CEO Robert Musslewhite resigned effective Jan 16, 2024; departure is without cause; receives 15 months accelerated vesting and up to $15K in legal fees.
Definitive Healthcare cuts 154 jobs, expects $6.5M-$7.2M restructuring charges
Workforce reduced by 154 employees as part of restructuring plan announced Jan 3, 2024.
Definitive Healthcare Q3 revenue $65.3M (+14% YoY); net loss widens to $248.7M on non-cash charges
Revenue $65.3M, up 14% YoY from $57.4M; above high-end of guidance.
Definitive Healthcare names Carrie Lazorchak as CRO; Mirisola to depart Dec 31
CRO Joe Mirisola resigns effective Nov 1, 2023; remains Senior Advisor through Dec 31, 2023.
Definitive Healthcare Q2 revenue $61M (+12% YoY), acquires Populi; guides Q3 rev $63-64.5M
Revenue $61.0M (+12% YoY); net loss widened to $11.6M from $10.1M; adjusted EBITDA $17.2M (28% of revenue).
Restates 2020-2022 and Q1 2023 financials over sales tax; expects G&A expense increase of $6.8M-$10.2M.
Definitive Healthcare Q1 revenue $59.2M (+18% YoY); net loss $15.6M
Revenue $59.2M (+18% YoY from $50.1M); net loss $15.6M vs $13.1M prior year.
Definitive Healthcare Q4 revenue up 31% to $60.6M; FY23 guidance implies 14% growth
Q4 revenue $60.6M (+31% YoY); GAAP net income $6.7M vs loss $14.8M in Q4 2021.
Revenue $57.4M (+33% YoY), net loss $6.4M vs $21.0M; adjusted EBITDA $16.4M (29% revenue).
Definitive Healthcare Q2 revenue $54.5M (+37% YoY); net loss narrows; raises FY guidance
Revenue $54.5M (+37% YoY); net loss ($9.6M) improved from ($15.0M) in Q2 2021.
Definitive Healthcare Q1 revenue $50.1M (+36% YoY); CEO transition to Musslewhite in August
Revenue $50.1M, +36% YoY; net loss ($13.1M) widened from ($10.5M); adjusted net income $7.7M (vs $2.6M).
Definitive Healthcare Q4 revenue up 38% to $46.3M; acquires Analytical Wizards for $65M
Q4 revenue $46.3M (+38% YoY); GAAP net loss $14.8M, adjusted net income $6.6M.
Definitive Healthcare Q3 revenue up 43% to $43.1M; GAAP net loss widens to $21M
Revenue $43.1M (+43% YoY); adjusted EBITDA $14.4M (33% margin) vs $14.5M (48% margin) a year ago.
Definitive Healthcare appoints former OptumInsight CEO Robert Musslewhite as President
Robert Musslewhite appointed President, a newly created role, effective Oct 7, 2021; he had been a board member since June 2021.
Definitive Healthcare closes IPO of 17.9M shares at $27, raising ~$483M
Closed IPO of 17,888,888 shares (includes overallotment) at $27.00/share, gross proceeds ~$483M.
The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.
On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025.
Richard Booth, the Company’s Chief Financial Officer, and the Company agreed that Mr. Booth will be leaving the Company effective June 1, 2025.
On September 29, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) promoted Kate Shamsuddin Jensen, the Company’s current Chief Strategy Officer, to the role of Chief Operating Officer, effective as of October 1, 2024 (the “Effective Date”).
On July 24, 2024, Carrie Lazorchak, the Chief Revenue Officer of the Company, provided the Company with notice of her resignation, effective August 2, 2024.
On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).
Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.
On January 12, 2024, the Company’s Board of Directors appointed Jason Krantz, the Company’s founder and Executive Chairman, as Interim Chief Executive Officer, effective January 16, 2024.
On January 16, 2024, the Company announced that Robert Musslewhite has stepped down as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors, effective January 16, 2024
In addition, Mr. Mirisola will cease to be Chief Revenue Officer effective November 1, 2023 and will, at such time, become a Senior Advisor.
Following Mr. Mitchell’s resignation, on September 6, 2023, the Board appointed Scott Stephenson as a member of the Board and as a member of the Nominating and Corporate Governance Committee of the Board.
On September 6, 2023, Chris Mitchell resigned from the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”), which resignation became effective upon the appointment of Scott Stephenson as a member of the Board on September 6, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings